Is Ledipasvir compatible with breastfeeding? Do we have alternatives for Ledipasvir?

Ledipasvir

August 6, 2017 (Low Risk)

Usually used in combination with sofosbuvir in the treatment of hepatitis C.

Since the last update we have not found published data on its excretion in breast milk.

Its pharmacokinetic data (high molecular weight and very high percentage of plasma protein binding) make it very unlikely that significant amounts will pass into breast milk, so that, although there is disagreement (Thompson 2016), some authors consider that treatment with ledispavir, alone or in combination with sofosbuvir is not contraindicated during breastfeeding (Spera 2016).


See below the information of these related products:

Alternatives

Very Low Risk

Compatible. Not risky for breastfeeding or infant.

Low Risk

Moderately safe. Mild risk possible. Follow up recommended. Read the Comment.

High Risk

Poorly safe. Evaluate carefully. Use a safer alternative. Read the Comment.

Very High Risk

Not recommended. Cessation of breastfeeding or alternative.

Writings

  • ليديباسفير (Arabic)
  • Ледипасвир (Cyrillic)
  • 来迪派韦 (Chinese)
  • C49H54F2N8O6 (Molecular formula)
  • G5-5885 (Experimental code/s)

Drug trade names

References

  1. EMA. Ledipasvir/Sofosbuvir (Harvoni). Ficha técnica. 2017 Full text (in our servers)
  2. EMA. Ledipasvir/Sofosbuvir (Harvoni). Drug Summary. 2017 Full text (in our servers)
  3. Thompson AJ. Australian recommendations for the management of hepatitis C virus infection: a consensus statement. Med J Aust. 2016Abstract Full text (link to original source) Full text (in our servers)
  4. Spera AM, Eldin TK, Tosone G, Orlando R. Antiviral therapy for hepatitis C: Has anything changed for pregnant/lactating women? World J Hepatol. 2016Abstract Full text (link to original source) Full text (in our servers)